Payment overview · 2025
General Payments
$949.79
31 reported records · 11 companies
Healthcare provider profile · identity verified
Blessilda Boholst Liu, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HERNANDO, FL · NPI 1720022601
Verified facts
What the public records show
CMS Open Payments records show Blessilda Boholst Liu, MD received $949.79 in general payments during 2025 across 31 reported records.
Astellas Pharma US Inc accounted for 27.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Veozah.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Veozah by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $261.30 | 27.5% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $201.59 | 21.2% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $178.46 | 18.8% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $125.00 | 13.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.63 | 5.8% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $45.87 | 4.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.03 | 2.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.99 | 2.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.11 | 1.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.17 | 1.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.64 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $764.80 | 29 |
| Education | $184.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $201.59 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $178.46 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $76.59 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $76.31 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $45.87 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.89 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.89 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $25.74 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 89 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 55 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 144 | exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
55 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
144 | 41 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 629 | 182 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 620 | 180 |
| Levothyroxine Sodium | Levothyroxine Sodium | 613 | 154 |
| Amlodipine Besylate | Amlodipine Besylate | 585 | 174 |
| Losartan Potassium | Losartan Potassium | 505 | 140 |
| Metformin Hcl | Metformin Hcl | 290 | 87 |
| Lisinopril | Lisinopril | 282 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 265 | 76 |
| Ezetimibe | Ezetimibe | 244 | 80 |
| Azithromycin | Azithromycin | 223 | 176 |
| Pravastatin Sodium | Pravastatin Sodium | 223 | 62 |
| Gabapentin | Gabapentin | 206 | 67 |
| Alprazolam | Alprazolam | 194 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 180 | 54 |
| Trazodone Hcl | Trazodone Hcl | 179 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 168 | 51 |
| Sertraline Hcl | Sertraline Hcl | 165 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 160 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 43 |
| Simvastatin | Simvastatin | 151 | 46 |
| Omeprazole | Omeprazole | 144 | 60 |
| Ozempic | Semaglutide | 144 | 41 |
| Famotidine | Famotidine | 138 | 45 |
| Montelukast Sodium | Montelukast Sodium | 128 | 36 |
| Allopurinol | Allopurinol | 120 | 34 |
| Atenolol | Atenolol | 114 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 33 |
| Prednisone | Prednisone | 109 | 94 |
| Furosemide | Furosemide | 107 | 29 |
| Eliquis | Apixaban | 104 | 29 |
| Glimepiride | Glimepiride | 104 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 31 |
| Potassium Chloride | Potassium Chloride | 96 | 32 |
| Jardiance | Empagliflozin | 89 | 27 |
| Synthroid | Levothyroxine Sodium | 88 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 83 | 65 |
| Methylprednisolone | Methylprednisolone | 78 | 58 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 40 |
| Donepezil Hcl | Donepezil Hcl | 70 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 16 |
| Amoxicillin | Amoxicillin | 66 | 58 |
| Lorazepam | Lorazepam | 65 | 21 |
| Valsartan | Valsartan | 60 | 20 |
| Alendronate Sodium | Alendronate Sodium | 59 | 19 |
| Estradiol | Estradiol | 58 | 24 |
| Meloxicam | Meloxicam | 58 | 24 |
| Carvedilol | Carvedilol | 56 | 19 |
| Mounjaro | Tirzepatide | 55 | 14 |
| Bupropion Xl | Bupropion Hcl | 52 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 15 |
| Clonazepam | Clonazepam | 49 | suppressed |
| Vascepa | Icosapent Ethyl | 49 | 15 |
| Irbesartan | Irbesartan | 45 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 43 | 16 |
| Buspirone Hcl | Buspirone Hcl | 41 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 27 |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Nystatin | Nystatin | 38 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 12 |
| Gemfibrozil | Gemfibrozil | 36 | 12 |
| Lovastatin | Lovastatin | 36 | 12 |
| Xarelto | Rivaroxaban | 35 | 11 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Torsemide | Torsemide | 32 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 26 |
| Fluconazole | Fluconazole | 28 | 18 |
| Baclofen | Baclofen | 27 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 23 |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 19 |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Vimpat | Lacosamide | 24 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | 20 |
| Cephalexin | Cephalexin | 23 | 20 |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 13 |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 19 |
| Finasteride | Finasteride | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Veozah | Fezolinetant | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 11 |
| Folic Acid | Folic Acid | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Keppra | Levetiracetam | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $949.79 · 31 records | Astellas Pharma US Inc | FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, KISUNLA, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, REPATHA, Rybelsus, Veozah, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error